A novel splicing mutation in SLC9A6 in a boy with Christianson syndrome

Daisuke Ieda1, Ikumi Hori1, Yuji Nakamura1, Kei Ohashi1, Yutaka Negishi1, Ayako Hattori1, Atsuko Arisaka2, Setsuko Hasegawa2,3 and Shinji Saitoh1

Abstract

A loss of function mutation in SLC9A6 (Xq26.3) is responsible for Christianson syndrome in males. We identified a novel splicing mutation (NM_006359.2:c.1141-8C>A) of SLC9A6 in a seven-year-old boy with microcephaly, severe developmental delay, and intractable epilepsy. Functional analysis found multiple aberrant transcripts, none of which maintained the canonical open reading frame. Computer prediction tools, however, failed to detect all of the aberrant transcripts.

A loss of function mutation in the SLC9A6 gene (Xq26.3) is responsible for Christianson syndrome (CS), which is characterized by severe global developmental delay, developmental regression, acquired microcephaly, intractable epilepsy, ataxia, ophthalmoplegia, and sometimes, death at a young age1,2. The clinical features of CS overlap with those of Angelman syndrome (AS), which is caused by a lack of expression of the maternally inherited UBE3A gene located on 15q11.23. SLC9A6 encodes the Na+/H+ exchanger protein NHE6. This protein regulates the luminal pH of early and recycling endosomes involved in the trafficking of proteins essential for structural and functional plasticity at glutamatergic synapses4. NHE6 has an important role in the growth of dendritic spines and the development of normal brain wiring5. Here, we identified a novel SLC9A6 splicing mutation in a seven-year-old boy with microcephaly, severe developmental delay, and intractable epilepsy. To evaluate the mutation, we used various computer prediction tools as well as reverse transcription polymerase chain reaction (RT-PCR) and cloning to assess transcripts and confirm the pathogenicity of the mutation.

The case study, a seven-year-old Japanese boy, was born at term with a birth weight of 2978 g (−0.4 SD), length of 50.2 cm (+0.4 SD), and head circumference of 31.4 cm (−1.5 SD). His development delayed gradually, achieving head control at four months, sitting at nine months, and pulling to stand at two years. Currently, he cannot stand independently nor speak meaningful words. At 10 months of age, he developed intractable seizures of variable types: tonic-clonic convulsion, impairment of consciousness, focal seizure, and epileptic negative myoclonus. He was treated with multiple antiepileptic drugs that had insufficient therapeutic effects. An electroencephalography (EEG) performed at four years showed focal epileptic discharges with generalization in multiple foci (Fig. 1a). At four years of age, his weight was 14.5 kg (−0.7 SD), length was 102 cm (−0.1 SD), and head circumference was 46.2 cm (−2.6 SD), indicating microcephaly. Brain magnetic resonance imaging (MRI) (performed at 1, 2, and 4 years of age) and magnetic resonance spectroscopy (MRS) (performed at 4 years of age) showed no abnormal findings (Fig. 1b, c). At five years of age, we suspected the diagnosis of AS due to severe developmental delay, trunk ataxia, intractable seizures, microcephaly, and frequent smiling.

We first performed genetic tests, including fluorescent in situ hybridization (FISH), DNA methylation, and mutation analysis of the protein coding exons of UBE3A.
by Sanger sequencing, but all of the tests were normal. Next, we performed targeted next-generation sequencing with the Ion Torrent Personal Genome Machine system (Life Technologies, Carlsbad, California). An amplicon library of the target exons and flanking sequence was prepared with the use of an Ion AmpliSeq Custom Panel (Life Technologies), which included **UBE3A**, **SLC9A6**, **TCF4**, **MBD5**, **CDKL5**, **MECP2**, and **FOXG1**. Sequence analysis pipelines were established with use of the workflow in CLC Genomic Workbench 7.0 (CLC bio, Aarhus, Denmark). We identified a **de novo** hemizygous splicing mutation (c.1141-8C>A) in **SLC9A6** (NM_006359.2), which was confirmed by Sanger sequencing using the **SLC9A6**-intron 9-Fwd (5'-TCCACATTGCTCCCTTC T-3') and **SLC9A6**-exon 10-Rev (5'-ACCACATC TCA AAACCACAC-3') primer pair (Fig. 1d). We predicted that the mutation affected RNA splicing because it resulted in a new AG acceptor site six nucleotides upstream of the canonical acceptor site of exon 10.

To evaluate the mutation, we used multiple computer prediction tools. CRYP-SKIP (http://cryp-skip.img.cas.cz/) provides an overall probability of cryptic splice-site activation (as opposed to exon skipping) termed P<sub>CR,E</sub>. P<sub>CR,E</sub> calculates a value between 0 and 1, and lower values favor exon skipping. The P<sub>CR,E</sub> prediction score for **SLC9A6** (c.1141-8C>A) was 0.20, thus favoring exon skipping. Next, we used Alamut Visual software (version 2.10, Interactive Biosoftware, Rouen, France), which assesses genomic sequences (wild type and mutant) using five splicing prediction tools (SpliceSiteFinder-like, MaxEntScan, Neural Network Splice, GeneSplicer, and Human Splicing Finder) based on different algorithms. All five algorithms predicted a strength reduction in the canonical acceptor site. The prediction scores for the aberrant acceptor site (six nucleotides upstream of the canonical acceptor site) increased with three algorithms, and the scores did not change at any point downstream of the canonical acceptor site (Table 1).

To confirm the RNA splicing results, we performed RT-PCR, cloning, and Sanger sequencing using total RNA from Epstein-Barr virus-induced lymphoblastoid cell lines established from peripheral leukocytes. RT-PCR using the **SLC9A6**-exon 8-Fwd1 (5'-ACCACATC TCA AAACCACAC-3') and **SLC9A6**-exon 12-Rev2 (5'-ACCACACAA TACCCACAC-3') primer pair revealed the presence of multiple transcripts (Fig. 1e). **SLC9A6** cDNA was then ligated into a TOPO cloning vector (Life Technologies) and transformed into TOP10 Competent Cells (Life Technologies), and 24 colonies were screened by extracting plasmid DNA using a QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany). Sanger sequencing of the plasmid clones identified four unique, aberrant transcripts but no canonical transcripts. Of the 24 cDNA transcripts screened, five (21%) had the six-nucleotide addition of the intronic sequence to the 5’ end of exon 10 that was predicted by our in silico analysis (Fig. 1f, transcript (a)). We also identified five (21%) transcripts and one (4%) transcript with 5’ exon 10 deletions of 28 and 30 nucleotides.
respectively, as well as 13 transcripts (54%) with complete skipping of exon 10 (Fig. 1f, transcripts (b), (c), and (d)). Furthermore, we performed RT-PCR using the SLC9A6-exon 8-Fwd1 and SLC9A6-exon9_10-Rev1 (5′-GCTCAAAACACTGTTAGTTCA-3′) primer pair, which amplified only canonical transcripts, and it revealed canonical transcripts in control DNA but no amplification in that of the patient.

CS was first reported in 1999 in a Caucasian South African family with multiple affected males presenting with severe intellectual disability, mutism despite apparently normal hearing, intractable epilepsy, and limited life expectancy1. As some of the clinical features of CS are shared with AS, 1.8–5.5% patients with AS-like phenotypes have SLC9A6 mutations3,8. The characteristic features that distinguish CS from AS are external ophthalmoplegia, developmental regression with loss of motor skills, progresive atrophy of the inferior cerebellar vermis, and an increased glutamine-glutamate peak in the basal ganglia on MRS9. Our patient, however, did not show any of these characteristic features at seven years of age. Pescosolido et al. reported that CS patients had regression in walking (57%), eating (14%), loss of few words/sounds (57%), eye contact/facial expressions (14%) and other fine/gross motor skills (14%) after a medical illness and/or seizure cluster10; therefore, we intend to follow our patient carefully.

Using target sequencing, we identified a de novo hemizygous intronic mutation (c.1141-8C>A) in SLC9A6 (NM_006359.2), which resulted in a new AG acceptor site (c.1141-8C>A) mutation is pathogenic. Comparing computer predictions to RNA transcript analysis, transcripts (a) and (d) were predicted by Alamut

| Table 1 In silico and functional splicing analysis from five prediction algorithms and in vitro RT-PCR analysis of mRNA transcripts |
|---------------------------------|-------|---------|-------|---------|-------|---------|-------|---------|-------|-------|-------|-------|
| cDNA position<sup>a</sup>       | SSF (0–100) | MaxEntScan (0–16) | NNSPLICE (0–1) | GeneSplicer (0–21) | HSF (0–100) | In vitro observed mRNA transcripts |
|                                 | WT     | MUT     | WT     | MUT     | WT     | MUT     | WT     | MUT     | WT     | MUT     | WT     | MUT     | WT     | MUT     |
| **Canonical splice site**       |        |         |        |         |        |         |        |         |        |         |        |         |        |         |
| c.1141                          | 82.52  | NE      | 8.27   | 1.58    | 0.74   | NE      | 2.77   | NE      | 88.42  | 85.82   | 0%     |         |        |         |
| **Cryptic splice site**         |        |         |        |         |        |         |        |         |        |         |        |         |        |         |
| c.1141-6                        | NE     | 76.86   | NE     | 5.30    | NE     | NE      | NE     | NE      | NE     | 78.15   | 21%    |         |        |         |
| c.1150                          | 83.44  | 83.44   | 6.12   | 6.12    | 0.64   | 0.64    | NE     | NE      | NE     | 72.75   | 72.75  | 0%     |         |         |
| c.1169                          | 72.43  | 72.43   | NE     | NE      | NE     | NE      | NE     | NE      | NE     | 76.93   | 76.93  | 4%     |         |         |
| c.1171                          | 72.43  | 72.43   | NE     | NE      | NE     | NE      | NE     | NE      | NE     | 76.93   | 76.93  | 4%     |         |         |
| c.1121                          | 88.37  | 88.37   | 8.92   | 8.92    | 0.67   | 0.67    | NE     | NE      | NE     | 91.52   | 91.52  | 0%     |         |         |

SSF Splice Site Finder-like, HSF Human Splicing Finder, WT wild type, MUT mutant, NE not evaluated

<sup>a</sup>First nucleotide of the acceptor splice site
visual and CRYP-SKIP, respectively, but transcripts (b) and (c) were not predicted. Previous studies comparing the functional consequences of splice site mutations in \textit{HR} (using CRYP-SKIP)\textsuperscript{12} and \textit{MYBPC3}, \textit{ACTC1}, and \textit{SCN5A} (using Alamut analysis)\textsuperscript{7} concluded that prediction programs underestimate the impact of intronic mutations and that functional analyses, such as RT-PCR and minigene analysis, are necessary. In our experience, computer prediction tools predicted two of the four aberrant transcripts detected by RT-PCR, highlighting the need to develop more accurate computer prediction tools.

HGV database
The relevant data from this Data Report are hosted at the Human Genome Variation Database at https://doi.org/10.6084/m9.figshare.hgv.2543

Acknowledgements
We thank the patient and family who participated in our study.

Author details
1Department of Pediatrics and Neonatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. 2Department of Pediatrics, Tokyo-Kita Medical Center, Tokyo, Japan. 3Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 6 August 2018 Revised: 10 January 2019 Accepted: 18 February 2019. Published online: 25 March 2019

References
1. Christianson, A. L. et al. X linked severe mental retardation, craniofacial dysmorphology, epilepsy, ophthalmoplegia, and cerebellar atrophy in a large South African kindred is localised to Xq24-q27. \textit{J. Med. Genet.} \textbf{36}, 759–766 (1999).
2. Schroer, R. J. et al. Natural history of Christianson syndrome. \textit{Am. J. Med. Genet. A.} \textbf{152A}, 2775–2783 (2010).
3. Gillilan, G. D. et al. SLC9A6 mutations cause X-linked mental retardation, microcephaly, epilepsy, and ataxia, a phenotype mimicking Angelman syndrome. \textit{Am. J. Hum. Genet.} \textbf{82}, 1003–1010 (2008).
4. Deane, E. C. et al. Enhanced recruitment of endosomal Na\textsuperscript{+}/H\textsuperscript{+} exchanger NHE6 into Dendritic spines of hippocampal pyramidal neurons during NMDA receptor-dependent long-term potentiation. \textit{J. Neurosci.} \textbf{33}, 595–610 (2013).
5. Takahashi, Y. et al. A loss-of-function mutation in the SLC9A6 gene causes X-linked mental retardation resembling Angelman syndrome. \textit{Am. J. Med. Genet. B. Neuropsychiatr. Genet.} \textbf{156B}, 799–807 (2011).
6. Divina, P., Kvitkovicova, A., Buratti, E. & Vorechovsky, I. Ab initio prediction of mutation-induced cryptic splice-site activation and exon skipping. \textit{Eur. J. Hum. Genet.} \textbf{17}, 759–765 (2009).
7. Frizzo, G. et al. Functional studies and in silico analyses to evaluate non-coding variants in inherited cardiomyopathies. \textit{Int. J. Mol. Sci.} \textbf{17}, 1883 (2016).
8. Fichou, Y. et al. Mutation in the SLC9A6 gene is not a frequent cause of sporadic Angelman-like syndrome. \textit{Eur. J. Hum. Genet.} \textbf{17}, 1378–1380 (2009).
9. Tan, W.-H., Bird, L. M., Thibert, R. L. & Williams, C. A. If not Angelman, what is it? a review of Angelman-like syndromes. \textit{Am. J. Med. Genet. A.} \textbf{164A}, 975–992 (2014).
10. Pescosolido, M. F. et al. Genetic and phenotypic diversity of NHE6 mutations in Christianson syndrome. \textit{Ann. Neurol.} \textbf{76}, S81–593 (2014).
11. Zanni, G. et al. A novel mutation in the endosomal Na\textsuperscript{+}/H\textsuperscript{+} exchanger NHE6 (SLC9A6) causes Christianson syndrome with electrical status epilepticus during slow-wave sleep (ESES). \textit{Epilepsy Res.} \textbf{108}, 811–815 (2014).
12. Refke, M. et al. Functional analysis of splice site mutations in the human hairless (HR) gene using a minigene assay. \textit{Br. J. Dermatol.} \textbf{165}, 1127–1132 (2011).